A double‐blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis
暂无分享,去创建一个
[1] P. Usai,et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double‐blind, double‐dummy, randomized multicentre study , 2001, Alimentary pharmacology & therapeutics.
[2] A. Cross,et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis , 2000 .
[3] Taylor,et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months , 1998, Alimentary pharmacology & therapeutics.
[4] R G Newcombe,et al. Transdermal nicotine for active ulcerative colitis. , 1994, The New England journal of medicine.
[5] S. Hanauer,et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.
[6] C. Holdsworth,et al. Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine , 1992, Alimentary pharmacology & therapeutics.
[7] Douglas G. Altman,et al. Practical statistics for medical research , 1990 .
[8] P. Cann,et al. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. , 1989, Gut.
[9] Ami,et al. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.
[10] J. G. Walker,et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine , 1988, Alimentary pharmacology & therapeutics.
[11] S. Riley,et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. , 1988, Gut.
[12] K Heinkel,et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. , 1980, The New England journal of medicine.
[13] J. V. van Tongeren,et al. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. , 1980, Gut.
[14] S. Truelove,et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. , 1980, Gut.
[15] S. Truelove,et al. AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.
[16] R. Carpenter,et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis , 1964, Gut.
[17] S. Truelove,et al. Comparison of Corticosteroid and Sulphasalazine Therapy in Ulcerative Colitis , 1962, British medical journal.
[18] J. H. Baron,et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. , 1962, Lancet.
[19] F. Jones,et al. An Assessment of Prednisone, Salazopyrin, and Topical Hydrocortisone Hemisuccinate Used as Out-patient Treatment for Ulcerative Colitis , 1960, Gut.
[20] G. May,et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2002, The Cochrane database of systematic reviews.
[21] G. May,et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. , 2000, The Cochrane database of systematic reviews.
[22] A. Lobo,et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. , 1998, Gastroenterology.
[23] R. Motley,et al. Does smoking improve colitis? , 1989, Scandinavian journal of gastroenterology. Supplement.
[24] B. Rathbone,et al. Possible pathogenetic pathways of Campylobacter pylori in gastro-duodenal disease. , 1988, Scandinavian journal of gastroenterology. Supplement.
[25] C. P. Willoughby,et al. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. , 1988, Scandinavian journal of gastroenterology. Supplement.